Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (? 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Stock Information for Autolus Therapeutics plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Autolus Therapeutics plc

Autolus Therapeutics to Participate in Upcoming Investor Conferences
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
Autolus Therapeutics to host virtual event to discuss the company's obe-cel program in systemic lupus erythematosus
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.